CSL Limited’s AEGIS-II trial of CSL112 fails to meet primary endpoint in heart attack patients

CSL Limited (ASX:CSL; USOTC:CSLLY), a renowned global biotechnology leader, disclosed the top-line outcomes from its eagerly anticipated Phase 3 AEGIS-II trial. This pivotal study assessed ... Read More